Creekwood Pharmaceuticals announced today that the FDA has approved its Abbreviated New Drug Application (ANDA #219460), signaling the entry of the company into this therapeutic segment. Given the product has no current brand competition, the approval is expected to generate immediate multi-million dollar revenue, positioning Creekwood for significant near-term earnings growth.